Epoprostenol-induced hypersplenism in portopulmonary hypertension

American Journal of the Medical Sciences

Volumn 344, Issue 5, 2012, Pages 345-349

  Touma, Waseem ^a   Nayak, Ravi P ^a   Hussain, Zulfiqar ^a   Bacon, Bruce R ^a   Kudva, Ganesh C ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epoprostenol; Hypersplenism; Pancytopenia; Portopulmonary hypertension; Splenomegaly

Indexed keywords

DANAZOL; DILTIAZEM; INTERFERON; PROSTACYCLIN; RIBAVIRIN; SILDENAFIL; STEROID; VINCRISTINE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; EPISTAXIS; ESOPHAGOGASTRODUODENOSCOPY; EXERTIONAL DYSPNEA; FEMALE; HEPATITIS C; HUMAN; HYPERSPLENISM; LIVER CIRRHOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PORTOPULMONARY HYPERTENSION; PULMONARY HYPERTENSION; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE TRANSFUSION;

EID: 84871619146     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31824184b1     Document Type: Article

References (29)

1. Swanson KL, Wiesner RH, Nyberg SL. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008;8:2445-53.
2. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44:1502-10.
3. Ramsay MAE, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3: 494-500.
4. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562-76.
5. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonaryhypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401-9.
6. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 2001;71:572-4.
7. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-51.
8. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-8.
9. Bozbas SS, Eyuboglu FO, Arslan NG, et al. The prevalence and the impact of portopulmonary hypertension on postoperative course inpatients undergoing liver transplantation. Transplant Proc 2009;41: 2860-3.
10. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174-82.
11. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:451-2.
12. Findlay JY, Plevak DJ, Krowka MJ. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999;5:362-5.
13. Nayak RP, Li D, Matuschak GM. Portopulmonary hypertension. Curr Gastroenterol Rep 2009;11:56-63.
14. Klco JM, Geng B, Brunt EM, et al. Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility. Am J Hematol 2010;85:106-10.
15. Chang CS, Li CY, Cha SS. Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med 1993;117:981-5.
16. Kim MY, Baik SK. Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension. Korean J Gastroenterol 2009;54:143-8.
17. Sitzman J, Campbell K,Wu Y, et al. Prostacyclin production in acute, chronic and long-term experimental portal hypertension. Surgery 1994; 115:290-4.
18. Fulghum TG, DiMarco JP, Supple EW. Effect of prostacyclin on vascular capacity in the dog. J Clin Invest 1985;76:999-1006.
19. Noguchi K, Matsuzald T, Ojiri Y, et al. Prostacyclin causes splenic dilation and haematological change in dogs. Clin Exp Pharmacol Physiol 2006;33:81-8.
20. Nakagawa O, Tanaka I, Usui T, et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 1994;90:1643-7.
21. Mow B, Kumar S, Monahan KH, et al. Thrombocytopenia during epoprostenol infusion for primary pulmonary hypertension: is there arelation to dose? Blood 1998;92(10 Suppl 1 Pt l-2):87b.
22. Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;118:1229-30.
23. Hargett CW, Ahearn GS, Krichman AM, et al. Thrombocytopenia associated with chronic intravenous epoprostenol therapy. Chest 2004; 126(4 Suppl):760S.
24. Chin KM, Channick RN, De Lemos JA, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009;135:130-6.
25. Mituniewicz J, Rosenzweig EB. Thrombocytopenia in PAH patient improves with transition from IV epoprostenol to IV treprostinil. Am J Respir Crit Care Med 2010;181:A3340.
26. Tokarczyk T, Loftus S, Cannon Y, et al. Thrombocytopenia during chronic prostacyclin infusions in primary pulmonary hypertension. Circulation 1997;96(Suppl I):134 (abstract).
27. Sasaki Y, Takahashi T, Tanaka I, et al. Expression of prostacyclin receptor in human megakaryocytes. Blood 1997;90:1039-46.
28. Vittet D, Duperray C, Chevillard C. Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J Cell Physiol 1995;163:645-55.
29. Shen HW, Chen YL, Chern CY, et al. The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells. Prostaglandins Other Lipid Mediat 2007;83:231-6.